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 am here today to tell you a story about how the University of Kansas Medical 
Center has been building a National Cancer Institute (NCI)-designated Cancer 
Center, and some of the lessons we have learned from this extraordinary quest. 
We had already begun this effort 
when, in his September 2005 convocation 
speech at the Medical Center, then-
University of Kansas Chancellor Robert 
Hemenway announced that attaining NCI 
designation for our cancer center was the 
University’s number-one priority.  
His dream for Kansas, he said, “is 
nothing short of ending suffering and 
death from cancer.” 
A cancer survivor himself, Chancellor 
Hemenway understood the scope of the 
challenge. Cancer is the second most 
common cause of death in the United 
States. This year, it’s estimated that more 
than 1.5 million people will be diagnosed 
with cancer in the United States – more 
than 13,000 in Kansas. More than 5,200 
Kansans died of cancer in 2008.  
Obtaining NCI designation was, the 
Chancellor said, “our university's number-
one priority.” Then he repeated it. “Notice I 
did not say the Medical Center's number-
one priority. This initiative will require the 
resources of our entire University.” 
Chancellor Hemenway promised that 
KU would build its cancer center “not as a 
fortress but as a broad network of 
resources.” To secure those resources, he 
promised to work with elected officials at 
the state and federal levels and to enlist the 
KU Endowment Association, along with 
private citizens, foundations and 
corporations to become our partners. 
This was excellent news for us at the 
Medical Center. Fighting cancer was our 
priority because it touches so many lives – 
and because it affects every organ of the 
body, so many of our researchers could 
engage in the fight. And patients in our 
region had to travel too far to reach an 
NCI-designated center, which offers the 
most cutting-edge clinical trials.  
Fighting cancer was also a high 
priority at The University of Kansas 
Hospital, with whom we share a campus, 
physician-scientists and other resources. 
This gave us the advantage of being able to 
link clinical programs with science.  
And we were poised for a bi-campus 
effort, particularly because the University 
of Kansas School of Pharmacy in Lawrence 
had invested in state-of-the-art technology 
to quickly discover and develop new 
drugs. 
There was, however, a problem.  
I 
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Fighting cancer was now the entire 
University’s top priority – but in financial 
terms it was still mostly a dream. 
Following the Chancellor’s speech, there 
would be no sudden infusion of research 
funding or money to build new labs. It 
would be largely up to us to meet the 
challenge.  
I had come to the University of Kansas 
Medical Center in 2000 from Philadelphia, 
a city with four NCI-designated centers. 
Kansas had none. And very few KUMC 
faculty had ever led an effort to create an 
NCI-designated Cancer Center.  
We had done the math on what it 
would take to build an NCI-designated 
Cancer Center, and we knew that it was 
going to take a billion dollars. But an 
analysis provided by the Kansas 
Technology Enterprise Corporation 
showed that, 10 years after achieving 
designation, that initial $1 billion 
investment would return $1.3 billion to the 
Kansas economy every year. 
It was time to lead. 
 
Focusing on: Strengths and 
Uniqueness 
I understood that the NCI would not 
award us a designation simply because 
Kansas didn’t have such a center. We 
would need to develop a cancer center 
unlike any other. Fortunately, we had 
already been building areas of unique 
expertise. 
The University of Kansas Medical 
Center had been working on cancer since 
1969, with the establishment of the first 
American Cancer Society Professor of 
Clinical Oncology and financial support 
from the Kansas Masonic Foundation. 
During the early 1970s, the NCI awarded 
us funding to investigate the feasibility of 
establishing a clinical cancer research 
center in Kansas. By the 1990s, what was 
then known as The University of Kansas 
Cancer Center (KUCC) was experiencing 
steady growth in terms of funding and 
pioneering research. Such growth 
warranted formalizing the KUCC’s 
research arm as the Kansas Cancer 
Institute.  
Three things would make The 
University of Kansas Cancer Center 
unique: 1) our expertise in drug discovery, 
development and delivery; 2) our strong 
research in cancer prevention and control; 
and 3) the development of a community-
based approach to cancer research through 
the creation of the Midwest Cancer 
Alliance. 
To make this vision a reality, we 
needed a dynamic, experienced leader. In 
2004, the Kansas Masonic Foundation 
made a new pledge to raise $15 million to 
support cancer research over five years. 
That allowed us to recruit our Center’s first 
full-time director, Roy A. Jensen, MD, a 
nationally recognized breast cancer 
researcher and pathologist from the NCI-
designated Vanderbilt-Ingram Cancer 
Center. 
Dr. Jensen’s arrival fulfilled one 
essential criterion for NCI designation: 
“The director should be a highly qualified 
scientist and administrator with leadership 
experience and institutional authority to 
manage the center and further its scientific 
mission and objectives.”  
Surely his decision to leave Vanderbilt 
was made easier by the fact that he was 
coming home. Dr. Jensen was born in 
Gardner, Kansas, and earned his bachelor’s 
degree in biology and Chemistry from 
Pittsburg State University. Dr. Jensen is 
also a Mason. Recognizing the 
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organization’s more than 30 years of 
support, we renamed our cancer institute 
the Kansas Masonic Cancer Research 
Institute.  
Dr. Jensen knew he could build on an 
existing strength, and one of the things that 
already made us unique.  
Some of the country’s top drug 
developers are working in the 
Departments of Medicinal and 
Pharmaceutical Chemistry at the 
University of Kansas School of Pharmacy – 
the school is currently ranked number two 
among all Schools of Pharmacy in National 
Institutes of Health (NIH) funding and has 
been within the top five for the past eight 
years. These drug developers include Jeff 
Aube, PhD, whose laboratory focuses on 
the development of new synthetic 
techniques, total synthesis, and the study of 
peptidomimetics. The University also had a 
Center for Drug Delivery Research, 
directed by Valentino Stella, PhD. Dr. Stella 
is a world-renowned expert in 
pharmaceutical chemistry who holds a 
prized “Development of Dosage Forms 
and Delivery systems for Antitumor 
Agents” contract with the NCI. As a result, 
more than 40 percent of the discoveries 
from the NCI’s pipeline are made at the 
University of Kansas. Another asset on the 
Lawrence campus was the High 
Throughput Screening Laboratory, which 
allows researchers at the University to 
screen large chemical libraries of 
compounds – a technology more common 
to the pharmaceutical industry than to a 
college campus.  
Thinking about how to build on this 
foundation, Dr. Jensen began conversations 
with Scott Weir, PharmD, PhD, a 22-year 
veteran of the pharmaceutical industry. In 
early 2006, Dr. Weir joined The University 
of Kansas Cancer Center. With $8.1 million 
from the Kauffman Foundation and a 
challenge match of $8 million from KU 
Endowment, we were able to create the 
Institute for Advancing Medical 
Innovation, which Dr. Weir now leads. 
This drug discovery, development and 
delivery program applies industry best 
practices, leverages relationships with 
other institutions and industry partners 
and demands high performance from 
highly collaborative project teams.  
 We had succeeded in creating one of 
the three elements that will make us 
unique among NCI-designated Cancer 
Centers.  
Another unique element is the 
strength of our cancer control and 
population health program, particularly as 
it relates to minority and rural populations. 
We have numerous community-based 
research projects focused on health 
disparities. University of Kansas Medical 
Center researchers are currently 
investigating enhanced treatment for 
tobacco use among African American 
smokers; disease management of smoking 
in rural primary care; and implementation 
of the “Health for All” model within the 
Latino community of Kansas City.  
We are especially proud of our success 
with a smoking-cessation program 
designed for American Indians. The All 
Nations Breath of Life program, created in 
collaboration with the Native community, 
recognizes and respects that tobacco is a 
sacred plant to many American Indians 
and that ceremonial use is entirely different 
from recreational use. This month, the 
researchers at the forefront of this work 
will announce a $7.5 million NIH grant to 
establish a Center for American Indian 
Community Health. In collaboration with 
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other community partners, KUMC will 
lead a study of tobacco use, diet and 
exercise among tribal college students. The 
grant will also help set up a pipeline to 
attract American Indian high school and 
college students to the KU School of 
Medicine’s Masters of Public Health degree 
program and to careers in public health, 
working with Haskell Indian Nations 
University. 
The third aspect that makes our cancer 
center unique is the development of a 
community-based approach to cancer 
research through the creation of the 
Midwest Cancer Alliance. 
In 2007, we formed The Midwest 
Cancer Alliance to bring cutting-edge 
clinical trials, the latest prevention and 
screening tools and continuing education 
opportunities to a region-wide network of 
hospitals and health care organizations. 
From the Goodland Regional Medical 
Center near the Colorado border to the 
Children’s Mercy Hospitals and Clinics in 
downtown Kansas City, Missouri, we 
wanted to advance the quality and reach of 
cancer prevention, early detection, 
treatment and survivorship methods. 
Leading this effort is Gary Doolittle, 
MD, another native Kansan with deep 
connections to the rural parts of our state. 
People throughout the state have great 
affection for Dr. Doolittle, who brings 
health care to remote places in Kansas via 
telemedicine, twice-a-month trips to 
conduct an oncology outreach clinic at 
Hays Medical Center in western Kansas 
and monthly visits to the Horton oncology 
outreach clinic in the Northeast corner of 
the state. 
Strong in the knowledge that our 
Cancer Center is distinguished by these 
three unique and valuable elements, we 
proceeded to tell our story over and over 
again as we set about finding the resources 
necessary for NCI designation. 
 
Focusing On: Telling the Story and 
Gathering the Resources 
When you have to raise a billion 
dollars, you absolutely must keep your 
whole community focused on your 
strengths and successes.  
Some community leaders were 
already behind us, thanks to our strong 
presence in a report on economics and 
education. In early 2005, knowing that 
Kansas City’s future was threatened by a 
host of serious urban problems, the Greater 
Kansas City Community Foundation 
commissioned a blue ribbon task force of 
nationally recognized leaders to 
recommend ways the metro could 
transform itself and become competitive in 
the new, global knowledge economy.  
This task force was led by Benno 
Schmidt, Jr., PhD, chairman of the City 
University of New York and of the Edison 
Schools board, and a former president of 
Yale University. Dr. Schmidt was joined by 
a diverse group of national thought leaders 
who met with hundreds of people and 
exhaustively studied the region’s colleges, 
universities and statehouses. Having 
spoken with Dr. Schmidt, I was not 
surprised when his panel’s unflinching 
report concluded that KU Medical Center 
would play a crucial role in saving the life 
of a city. “KUMC is the only academic 
enterprise in Kansas City with the current 
capacity to generate a high quality and 
broad scope of basic research activity in a 
reasonable time with a high probability of 
success,” he wrote in Time to Get It Right. 
The panel ordered Kansas City’s business, 
philanthropic and political leaders to pour 
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hundreds of millions of dollars into our 
effort.  
We were also fortunate to have strong 
leadership from former Kansas Governor 
Kathleen Sebelius. Gov. Sebelius, a 
Democrat, was elected governor in 
November 2002. She had been active in 
insurance reform, having served as 
Kansas's insurance commissioner and as a 
member of the state legislature. She cared 
deeply about health issues, as was clear 
when President Barack Obama appointed 
her Secretary of Health and Human 
Services (HHS) in 2009. During the 2006 
session of the Kansas Legislature, Gov. 
Sebelius included in her budget for fiscal 
year 2007 an additional $5 million to 
support the development of the KU Cancer 
Center, highlighting the request in her 
“State of the State of Kansas” speech at the 
beginning of the session. With significant 
bipartisan support, legislators approved 
the appropriation.  
Gov. Sebelius continued to include 
this appropriation in subsequent years, 
which kept our efforts highly publicized. 
Kansas lawmakers continued to approve 
our $5 million appropriation each year 
since. Even during this time of declining 
revenues and painful cuts elsewhere, 
Kansas lawmakers understand the 
enormous potential for return on 
investment in the knowledge economy. 
After Gov. Sebelius left to lead HHS, her 
successor, Gov. Mark Parkinson, continued 
to support the cancer center appropriation. 
Moreover, he made the cancer fight easier 
by pushing for the Kansas Clean Indoor 
Air Act, which passed this year.  
State lawmakers also endorsed one of 
the more visible signs of our quest. In 2007, 
State Senator Barbara Allen pushed for 
legislation to create a license plate to 
support breast cancer research and 
outreach efforts across the state.  
Perhaps our most surprising show of 
public support came during the summer of 
2008. In the midst of a heated presidential 
campaign, supporters of the University of 
Kansas and Kansas State University – who 
are usually rivals – made a unified push to 
pass a 1/8-cent sales tax to support 
education and research in Johnson County, 
Kansas. I cannot overstate the significance 
of this election. In Johnson County, 
registered Republicans outnumber 
registered Democrats nearly 2 to 1. This is 
presumably an anti-tax crowd; moreover, 
an economic crisis was looming. Still, we 
found allies in the most unexpected places. 
For example, State Senator Karin Brownlee, 
a Republican from Olathe who generally 
opposes taxes, agreed to be an honorary co-
chair of this sales tax campaign.  
On November 4, 2008, 57 percent of 
the voters agreed to help pay for our work. 
Revenues from the tax will generate $5 
million a year – in perpetuity – for our 
Clinical Research Center, where we will 
conduct early-stage clinical trials of drugs 
in our pipeline. 
Additional extraordinary leadership 
and support has come from the Kansas 
Bioscience Authority (KBA), created in 
2004 with a state commitment of $581 
million to help build world-class research 
capacity, encourage bioscience startups and 
expand and attract bioscience industries in 
Kansas.  
Directed by Tom Thornton, who had 
previously served as president and chief 
executive officer of the well-regarded 
Illinois Technology Development Alliance, 
the KBA has played a pivotal role in the 
development of the animal research 
corridor from Manhattan, Kansas to 
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Columbia, Missouri. The KBA led the effort 
to secure the National Bio- and Agro-
defense Facility (NBAF), a government-run 
research facility that will develop 
countermeasures to combat high-
consequence biological threats involving 
human, zoonotic, and foreign animal 
diseases. Over a 10-year period, the KBA 
has committed more than $41.4 million to 
the Cancer Center NCI designation efforts. 
This money has funded basic research and 
clinical trials, allowed us to invest in 
technologies that expand drug delivery 
capabilities, significantly enhanced our 
ability to recruit talented researchers 
through their eminent scholar and rising 
star programs, and bankrolled major 
construction to create state-of-the-art 
laboratories. 
We couldn’t just focus on successes, 
though. We had to solve some real 
problems. 
 
Focus On: Overcoming Obstacles 
At this particular moment, the area’s 
civic and political leaders were acutely 
aware of the need to ensure a friendly 
environment for scientific research.  
Just five years earlier, cancer survivors 
Jim and Virginia Stowers had donated $2 
billion to create the Stowers Institute, the 
country’s second-largest privately 
endowed institute for basic medical 
research. When some Missourians led an 
effort to ban early stem cell research, the 
business community joined with scientists, 
religious leaders, medical professionals and 
citizens to campaign for a constitutional 
amendment protecting such research. 
Missouri voters passed that amendment in 
November 2006.  
Many of these same leaders also joined 
us to defeat a bill in the Kansas Legislature 
that would have banned early stem cell 
research. In March 2005, I testified before 
lawmakers to warn them that if they 
passed the bill, scientists wouldn’t want to 
come to Kansas. It was risky to speak up in 
that way, because the Kansas Legislature is 
often conservative and controls a 
significant portion of our budget. But it was 
a bigger risk not to testify. I focused on the 
scientific and educational aspects of the 
issue rather than the politics. I also gave 
well over a hundred “Stem Cell 101” 
education sessions to policymakers and 
interested citizens. As it turned out, we had 
strong support in the legislature and from 
the Governor. 
Still, despite all of the external 
momentum and support, internally not all 
of our department leaders understood how 
the focus on cancer designation would 
benefit them. We encountered resistance 
when we had to cut departmental budgets 
at the same time we were raising 
philanthropic dollars to recruit cancer 
researchers. Though the entire university 
system was enduring painful budget cuts, 
we needed to continue investing in the 
Cancer Center efforts. This internal effort 
required a different kind of focusing. 
Within the first two years of our quest, I 
replaced six of the department chairs. By 
the third year, all but five of our 25 
departments had new chairs. 
Our plan also required us to create 
partnerships with hospitals throughout the 
region. After long, hard discussions, we 
reached affiliation agreements with 
numerous hospitals, including a crucial 
agreement that strengthened our 
relationship with The University of Kansas 
Hospital. 
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Lessons of Leadership: Recruitment, 
Progress and Accountability 
I will end by highlighting just three of 
the lessons that stand out from the many 
we have learned while trying to create an 
NCI-designated Cancer Center at the 
University of Kansas Medical Center.  
First, recruiting is key and takes 
precedence.  
Our key hire was Dr. Jensen. But we 
also made early mistakes. We hired a 
renowned lung cancer specialist as our 
Cancer Center’s deputy director, but that 
didn’t work out. That recruitment failure 
set us back two years.  
Early in the process, we recruited 
junior faculty – they were promising but 
did not yet have NCI funding. We learned 
to be more strategic in our recruiting, and 
began hiring researchers who would bring 
their NCI funding with them.  
And we learned that we can’t expect 
Dr. Jensen to do everything. As the Cancer 
Center’s director, Dr. Jensen had done the 
critical work of educating the public, which 
resulted in the widespread support that has 
sustained our mission and momentum. But 
we were slow in the equally critical aspect 
of recruiting world-class researchers to fill 
key leadership posts.  
Eventually we hired a search firm to 
speed up the recruiting. That might be 
unheard of in the world of academic 
medicine – but we have now begun to fill 
those crucial posts. 
Second, recruiting takes incredible 
resources and enormous collaboration.  
In addition to the funds and space 
committed to this effort by the University – 
both from the Medical Center and 
Lawrence campus – we have benefited 
from the significant resources provided 
from The University of Kansas Hospital. 
Key recruits such as Parvesh Kumar, MD, 
were made possible with the help of the 
hospital and its philanthropic gifts. The 
state of Kansas, the Kansas Bioscience 
Authority and the voters of Johnson 
County, who approved the tax for the 
research triangle, have all provided 
necessary funding. The Kansas 
congressional delegation provided needed 
resources through specific Cancer Center 
earmarks, which have been aimed at 
purchasing cancer research equipment. 
And we are indebted to the numerous 
philanthropic supporters who have 
contributed money and time to champion 
our mission. The pace of fundraising has 
increased even in difficult economic times. 
Even with the many recent 
recruitment successes on both the Medical 
Center and main campuses, we still have a 
few key leadership positions to hire. The 
total estimated cost of five-year recruitment 
packages for a deputy director and 
associate directors of cancer prevention and 
control, translational research and basic 
sciences is $18.8 million. Recruitment is 
expensive, but it is one of the most critical 
aspects of our NCI designation application 
package. 
The good news is that we have 
candidates in the pipeline for all of these 
leadership positions, and are working 
diligently and creatively to find the 
resources necessary to bring these cancer 
physicians and scientists to our region. The 
Kansas Bioscience Authority’s support has 
been crucial to our recruitment efforts. 
Finally, with so much investment at 
stake, we have learned that tracking our 
progress and being accountable to our 
collaborators is crucial. Sharing our 
successes and setbacks has helped to build 
trust among the various stakeholders – 
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local communities, policymakers, the 
media and our own faculty.  
The NCI has invited us to apply as 
early as September 2011. A recent report 
from our External Advisory Board 
applauds our successes to date – but also 
suggests that we may need to be flexible in 
our application date. Given our 
momentum, however, we intend to stay 
the course. In fact, we are picking up the 
pace as we move toward the 2011 
submission date. 
Earlier this month, we were among the 
sponsors of a town hall meeting on the new 
role of academia in drug development and 
discovery. Along with the Friends of 
Cancer Research, the Kauffman 
Foundation, the Kansas Bioscience 
Authority and the Council for Advancing 
Medical Innovation, we hosted a well-
attended meeting of the minds. HHS 
Secretary Sebelius gave the keynote speech, 
and NIH Director Francis Collins, MD, 
PhD, and Food and Drug Administration 
Commissioner Dr. Margaret Hamburg, 
MD, participated in a panel on how to 
speed up the process of taking drugs from 
bench to bedside. Our model was among 
the examples of how it can be done. 
Although the lessons I have shared 
with you today outline the importance of 
resources, recruiting and accountability, it 
is important to keep in mind our end goal, 
which has guided us from the beginning.  
Yes, achieving NCI designation could 
create to 9,400 new jobs for the state, pump 
$1.3 million dollars into our state’s 
economy and almost double the amount of 
grant dollars for KU Cancer Center 
researchers. It would certainly bring a great 
deal of prestige to the University of Kansas. 
But most importantly, it would mean our 
families, friends and residents could stay in 
Kansas to get the highest quality cancer 
care in the country. 
 
